Fibrosarcoma: A review and update

Histopathology

Volumn 64, Issue 1, 2014, Pages 12-25

  Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dermatofibrosarcoma protuberans; Fibrosarcoma; Immunohistochemistry; Low grade fibromyxoid sarcoma; Molecular genetics; Sclerosing epithelioid fibrosarcoma

Indexed keywords

APOLIPOPROTEIN D; BLOOD CLOTTING FACTOR 13A; CD34 ANTIGEN; COL1A1 PDGFB FUSION PROTEIN; CYTOKERATIN; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; FUSED IN SARCOMA PROTEIN; HYBRID PROTEIN; IMATINIB; MUCIN 4; PROTEIN S 100; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT DISEASE; CANCER INCIDENCE; CANCER SURVIVAL; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; FIBROSARCOMA; GIANT CELL; HUMAN; IMMUNOHISTOCHEMISTRY; LOW GRADE FIBROMYXOID SARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; MITOSIS RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

DERMATOFIBROSARCOMA PROTUBERANS; FIBROSARCOMA; IMMUNOHISTOCHEMISTRY; LOW-GRADE FIBROMYXOID SARCOMA; MOLECULAR GENETICS; SCLEROSING EPITHELIOID FIBROSARCOMA;

FIBROSARCOMA; HUMANS; SOFT TISSUE NEOPLASMS;

EID: 84889658718     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12282     Document Type: Review

References (99)

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone. 4th ed. Lyons: IARC Press, 2013.
2. Meyerding H, Broders A, Hargrave R. Clinical aspects of fibrosarcoma of the soft tissues of the extremities. Surg. Gynecol. Obstet. 1936; 62; 1010-1019.
3. Stout AP. Fibrosarcoma the malignant tumor of fibroblasts. Cancer 1948; 1; 30-63.
4. Pritchard DJ, Soule EH, Taylor WF, Ivins JC. Fibrosarcoma - a clinicopathologic and statistical study of 199 tumors of the soft tissues of the extremities and trunk. Cancer 1974; 33; 888-897.
5. Scott SM, Reiman HM, Pritchard DJ, Ilstrup DM. Soft tissue fibrosarcoma. A clinicopathologic study of 132 cases. Cancer 1989; 64; 925-931.
6. Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am. J. Surg. Pathol. 2010; 34; 1504-1513.
7. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26, 758 cases. Int. J. Cancer 2006; 119; 2922-2930.
8. Russell WO, Cohen J, Enzinger F et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977; 40; 1562-1570.
9. Enzinger FM, Shiraki M. Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years. Cancer 1967; 20; 1131-1140.
10. Weiss SW. Proliferative fibroblastic lesions. From hyperplasia to neoplasia. Am. J. Surg. Pathol. 1986; 10(Suppl. 1); 14-25.
11. Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963; 16; 331-344.
12. O'Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer 1964; 17; 1445-1455.
13. Kempson RL, Kyriakos M. Fibroxanthosarcoma of the soft tissues. A type of malignant fibrous histiocytoma. Cancer 1972; 29; 961-976.
14. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978; 41; 2250-2266.
15. Enzinger FM. Malignant fibrous histiocytoma 20 years after Stout. Am. J. Surg. Pathol. 1986; 10(Suppl. 1); 43-53.
16. Dehner LP. Malignant fibrous histiocytoma. Nonspecific morphologic pattern, specific pathologic entity, or both? Arch. Pathol. Lab. Med. 1988; 112; 236-237.
17. Snover DC, Sumner HW, Dehner LP. Variability of histologic pattern in recurrent soft tissue sarcomas originally diagnosed as liposarcoma. Cancer 1982; 49; 1005-1015.
18. Brooks JJ. The significance of double phenotypic patterns and markers in human sarcomas. A new model of mesenchymal differentiation. Am. J. Pathol. 1986; 125; 113-123.
19. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma [see comments]. Am. J. Surg. Pathol. 1992; 16; 213-228.
20. Angervall L, Kindblom LG, Merck C. Myxofibrosarcoma. A study of 30 cases. Acta Pathol. Microbiol. Scand. A 1977; 85A; 127-140.
21. Mentzel T, Calonje E, Wadden C et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am. J. Surg. Pathol. 1996; 20; 391-405.
22. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer 1977; 39; 1672-1685.
23. Dal Cin P, Pauwels P, Sciot R, Van den Berghe H. Multiple chromosome rearrangements in a fibrosarcoma. Cancer Genet. Cytogenet. 1996; 87; 176-178.
24. Van den Berg E, Molenaar WM, Hoekstra HJ, Kamps WA, de Jong B. DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas. Mod. Pathol. 1992; 5; 505-514.
25. Limon J, Szadowska A, Iliszko M et al. Recurrent chromosome changes in two adult fibrosarcomas. Genes Chromosom. Cancer 1998; 21; 119-123.
26. Evans HL. Low-grade fibromyxoid sarcoma. A report of two metastasizing neoplasms having a deceptively benign appearance. Am. J. Clin. Pathol. 1987; 88; 615-619.
27. Devaney DM, Dervan P, O'Neill S, Carney D, Leader M. Low-grade fibromyxoid sarcoma. Histopathology 1990; 17; 463-465.
28. Evans HL. Low-grade fibromyxoid sarcoma. A report of 12 cases. Am. J. Surg. Pathol. 1993; 17; 595-600.
29. Nichols GE, Cooper PH. Low-grade fibromyxoid sarcoma: case report and immunohistochemical study. J. Cutan. Pathol. 1994; 21; 356-362.
30. Fukunaga M, Ushigome S, Fukunaga N. Low-grade fibromyxoid sarcoma. Virchows Arch. 1996; 429; 301-303.
31. Folpe AL, Lane KL, Paull G, Weiss SW. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am. J. Surg. Pathol. 2000; 24; 1353-1360.
32. Mezzelani A, Sozzi G, Nessling M et al. Low grade fibromyxoid sarcoma. A further low-grade soft tissue malignancy characterized by a ring chromosome. Cancer Genet. Cytogenet. 2000; 122; 144-148.
33. Lane KL, Shannon RJ, Weiss SW. Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma. Am. J. Surg. Pathol. 1997; 21; 1481-1488.
34. Matsuyama A, Hisaoka M, Shimajiri S et al. Molecular detection of FUS-CREB3L2 fusion transcripts in low-grade fibromyxoid sarcoma using formalin-fixed, paraffin-embedded tissue specimens. Am. J. Surg. Pathol. 2006; 30; 1077-1084.
35. Guillou L, Benhattar J, Gengler C et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am. J. Surg. Pathol. 2007; 31; 1387-1402.
36. Doyle LA, Moller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am. J. Surg. Pathol. 2011; 35; 733-741.
37. Evans HL. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up. Am. J. Surg. Pathol. 2011; 35; 1450-1462.
38. Laurini JA, Zhang L, Goldblum JR, Montgomery E, Folpe AL. Low-grade fibromyxoid sarcoma of the small intestine: report of 4 cases with molecular cytogenetic confirmation. Am. J. Surg. Pathol. 2011; 35; 1069-1073.
39. Billings SD, Giblen G, Fanburg-Smith JC. Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population. Am. J. Surg. Pathol. 2005; 29; 204-210.
40. Thway K, Fisher C, Debiec-Rychter M, Calonje E. Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. Hum. Pathol. 2009; 40; 1586-1590.
41. Reid R, de Silva MV, Paterson L, Ryan E, Fisher C. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation. Am. J. Surg. Pathol. 2003; 27; 1229-1236.
42. Bejarano PA, Padhya TA, Smith R, Blough R, Devitt JJ, Gluckman JL. Hyalinizing spindle cell tumor with giant rosettes - a soft tissue tumor with mesenchymal and neuroendocrine features. An immunohistochemical, ultrastructural, and cytogenetic analysis. Arch. Pathol. Lab. Med. 2000; 124; 1179-1184.
43. Storlazzi CT, Mertens F, Nascimento A et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum. Mol. Genet. 2003; 12; 2349-2358.
44. Mertens F, Fletcher CD, Antonescu CR et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab. Invest. 2005; 85; 408-415.
45. Panagopoulos I, Storlazzi CT, Fletcher CD et al. The chimeric FUS/CREB3 l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosom. Cancer 2004; 40; 218-228.
46. Wang WL, Evans HL, Meis JM et al. FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma. Mod. Pathol. 2012; 25; 846-853.
47. Rekhi B, Folpe AL, Deshmukh M, Jambhekar NA. Sclerosing epithelioid fibrosarcoma - a report of two cases with cytogenetic analysis of FUS gene rearrangement by FISH technique. Pathol. Oncol. Res. 2011; 17; 145-148.
48. Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am. J. Surg. Pathol. 1995; 19; 979-993.
49. Doyle LA, Wang WL, Dal Cin P et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am. J. Surg. Pathol. 2012; 36; 1444-1451.
50. Rekhi B, Deshmukh M, Jambhekar NA. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 18 cases, including histopathologic relationship with sclerosing epithelioid fibrosarcoma in a subset of cases. Ann. Diagn. Pathol. 2011; 15; 303-311.
51. Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am. J. Surg. Pathol. 2001; 25; 699-709.
52. Reid R, Barrett A, Hamblen DL. Sclerosing epithelioid fibrosarcoma. Histopathology 1996; 28: 451-455.
53. Eyden BP, Manson C, Banerjee SS, Roberts IS, Harris M. Sclerosing epithelioid fibrosarcoma: a study of five cases emphasizing diagnostic criteria. Histopathology 1998; 33; 354-360.
54. Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer 1962; 15; 717-725.
55. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am. J. Surg. Pathol. 2006; 30; 436-443.
56. Bowne WB, Antonescu CR, Leung DH et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 88; 2711-2720.
57. Morimitsu Y, Hisaoka M, Okamoto S, Hashimoto H, Ushijima M. Dermatofibrosarcoma protuberans and its fibrosarcomatous variant with areas of myoid differentiation: a report of three cases. Histopathology 1998; 32; 547-551.
58. Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous ('high-grade') dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am. J. Surg. Pathol. 1998; 22; 576-587.
59. Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S, Hashimoto H. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch. 1998; 433; 323-329.
60. Pizarro G, Fanburg J, Miettinen M. Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation: re-explored. Mod. Pathol. 1997; 10; 13A.
61. Diaz-Cascajo C, Weyers W, Borrego L, Inarrea JB, Borghi S. Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemic study in four cases. Am. J. Dermatopathol. 1997; 19; 562-567.
62. O'Connell JX, Trotter MJ. Fibrosarcomatous dermatofibrosarcoma protuberans with myofibroblastic differentiaion: a histologically distinctive variant [corrected]. Mod. Pathol. 1996; 9; 273-278.
63. Goldblum JR. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans. Arch. Pathol. Lab. Med. 1995; 119; 238-241.
64. Connelly JH, Evans HL. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. Am. J. Surg. Pathol. 1992; 16; 921-925.
65. Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors. Cancer 1989; 64; 721-729.
66. Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am. J. Surg. Pathol. 1988; 12; 287-293.
67. McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases - five with metastasis. Ann. Surg. 1967; 166; 803-816.
68. Burkhardt BR, Soule EH, Winkelmann RK, Ivins JC. Dermatofibrosarcoma protuberans. Study of fifty-six cases. Am. J. Surg. 1966; 111; 638-644.
69. Martin L, Combemale P, Dupin M et al. The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br. J. Dermatol. 1998; 139; 719-725.
70. Bague S, Folpe AL. Dermatofibrosarcoma protuberans presenting as a subcutaneous mass: a clinicopathological study of 15 cases with exclusive or near-exclusive subcutaneous involvement. Am. J. Dermatopathol. 2008; 30; 327-332.
71. Wacker J, Khan-Durani B, Hartschuh W. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann. Surg. Oncol. 2004; 11; 438-444.
72. Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004; 101; 28-38.
73. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue [see comments]. J. Am. Acad. Dermatol. 1993; 28; 613-617.
74. Cohen PR, Rapini RP, Farhood AI. Expression of the human hematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors [see comments]. J. Cutan. Pathol. 1993; 20; 15-20.
75. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans [comment]. Am. J. Dermatopathol. 1993; 15; 429-434.
76. Aiba S, Tabata N, Ishii H, Ootani H, Tagami H. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br. J. Dermatol. 1992; 127; 79-84.
77. West RB, Harvell J, Linn SC et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am. J. Surg. Pathol. 2004; 28; 1063-1069.
78. Bridge JA, Neff JR, Sandberg AA. Cytogenetic analysis of dermatofibrosarcoma protuberans. Cancer Genet. Cytogenet. 1990; 49; 199-202.
79. Patel KU, Szabo SS, Hernandez VS et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum. Pathol. 2008; 39; 184-193.
80. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosom. Cancer 2003; 37; 1-19.
81. Wang J, Hisaoka M, Shimajiri S, Morimitsu Y, Hashimoto H. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn. Mol. Pathol. 1999; 8; 113-119.
82. Pedeutour F, Simon MP, Minoletti F et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet. Cell Genet. 1996; 72; 171-174.
83. McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 2005; 23; 866-873.
84. Rutkowski P, Van Glabbeke M, Rankin CJ et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J. Clin. Oncol. 2010; 28; 1772-1779.
85. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 2002; 20; 3586-3591.
86. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer 2002; 100; 623-626.
87. Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer 1965; 18; 613-627.
88. Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer 1977; 39; 1201-1217.
89. Enzinger FM, Weiss SW. Soft tissue tumors. St Louis, MO: Mosby, 1983; ix, 840
90. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod. Pathol. 2009; 22; 872-878.
91. Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am. J. Surg. Pathol. 2009; 33; 1743-1751.
92. Sun B, Sun Y, Wang J et al. The diagnostic value of SYT-SSX detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma: a review and prospective study of 255 cases. Cancer Sci. 2008; 99; 1355-1361.
93. Terry J, Saito T, Subramanian S et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am. J. Surg. Pathol. 2007; 31; 240-246.
94. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol. 2004; 22; 4040-4050.
95. Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am. J. Surg. Pathol. 2002; 26; 1434-1440.
96. Antonescu CR, Kawai A, Leung DH et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn. Mol. Pathol. 2000; 9; 1-8.
97. Fisher C. Synovial sarcoma. Ann. Diagn. Pathol. 1998; 2; 401-421.
98. Coindre JM, Hostein I, Benhattar J, Lussan C, Rivel J, Guillou L. Malignant peripheral nerve sheath tumors are t(X;18)-negative sarcomas. Molecular analysis of 25 cases occurring in neurofibromatosis type 1 patients, using two different RT-PCR-based methods of detection. Mod. Pathol. 2002; 15; 589-592.
99. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20; 5755-5762.